Innovative Medicines Initiative reveals INNODIA’s clinical trial project

Article summary

The Innovative Medicines Initiative has announced that INNODIA—a global partnership between academic institutions, industrial partners, patient organisations and a small-sized enterprise, working together to fight type 1 diabetes—has developed a clinical trial master protocol that will speed up clinical trials for type 1 diabetes drugs, meaning that the disease can be cured faster. David Dunger, professor of paediatrics at the University of Cambridge and project lead on INNODIA’s work on the master protocol, explains that ‘the idea of a master protocol is that rather than starting off with a new protocol every time you want to do one of these studies, you have a protocol that can be re-used for different studies—a recyclable protocol’. This ‘recyclable protocol’ will make it considerably easier to perform clinical trials. Significantly, the European Medicines Agency has given approval to the master protocol and INNODIA is set to begin using the protocol for its own clinical trials.